Patents Examined by Aradhana Sasan
  • Patent number: 11660324
    Abstract: The present disclosure relates to the use of CuPTSM in methods and compositions for treating subjects with a neurodegenerative disease. Subjects with a neurodegenerative disease can have, e.g., amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: May 30, 2023
    Assignee: ALS THERAPY DEVELOPMENT INSTITUTE
    Inventors: Steven Perrin, Fernando G. Vieira, Alan Gill, Theo Hatzipetros, Kyle Denton, Matvey Lukashev
  • Patent number: 11654107
    Abstract: An animal treat composition for the oral administration of a medication to an animal is disclosed. The animal treat composition comprises an adhesive portion core and an outer portion. The adhesive portion adheres to oral medication inserted into the adhesive core of the treat for administration of the medication to an animal.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: May 23, 2023
    Assignee: JMN Technologies LLC
    Inventors: Mark A. Levin, Joanne N. Levin
  • Patent number: 11654155
    Abstract: It is an object to provide a therapeutic material for a skin ulcer which has excellent therapeutic effects on intractable skin ulcers such as decubitus ulcers with pockets and huge decubitus ulcers. By applying the therapeutic material for decubitus ulcers consisting of a fibrous material holding an antibiotic and a cell proliferation accelerator therein which is formed into an approximately spherical shape to a site of decubitus in a state in which a defect extending to the dermis, subcutaneous tissue, muscle or bone occurs, it is possible to treat critical skin ulcers such as intractable decubitus ulcers with pockets and huge intractable decubitus ulcers, as well as to treat not only relatively mild decubitus classified as stage II according to the US National Pressure Ulcer Advisory Panel (NPUAP) staging system, i.e.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: May 23, 2023
    Assignees: OMOIDESOUZOU CO., LTD.
    Inventor: Hideyasu Takata
  • Patent number: 11649269
    Abstract: The present invention relates to novel covalently linked bi-functional fusion proteins comprising insulin and EGF(A) analogues or derivatives thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such bi-functional compounds, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes and dyslipidaemia associated with diabetes.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: May 16, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Martin Werner Borchsenius Muenzel, Susanne Hostrup, Gro Klitgaard Povlsen, Mathias Norrman, Thomas Boerglum Kjeldsen, Claudia Ulrich Hjoerringgaard, Peter Madsen
  • Patent number: 11642315
    Abstract: A method of preparing a pharmaceutical product comprises the steps of (a) providing a neat active pharmaceutical ingredient (API) complying with at least five of the following parameters determined by using a FT4 powder rheometer: (i) specific basic flow energy of at most 60 mJ/g; (ii) stability index of 0.75 to 1.25; (iii) specific energy of at most 10 mJ/g; (iv) major principle stress at 15 kPa of at most 40; (v) flow function at 15 kPa of at least 1.3; (vi) consolidated bulk density at 15 kPa of at least 0.26 g/mL; (vii) compressibility of at most 47%; and (viii) wall friction angle of at most 40°; (b) dispensing the neat API of step (a) into a bottom part of a pharmaceutical carrier using a vacuum assisted metering and filling device; and (c) encapsulating the bottom part, thereby producing a pharmaceutical product.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: May 9, 2023
    Assignee: Novartis AG
    Inventors: Elodia Di Renzo, David Hook, Markus Krumme, Steffen Lang, Massimo Moratto, Joerg Ogorka, Jim Parks, Dale Ploeger, Norbert Rasenack, Hendrik Schneider, Stefan Steigmiller, Gordon Stout, Patrick Tritschler, Fabian Weber
  • Patent number: 11642416
    Abstract: The present invention provides a conjugate comprising an albumin binding peptide and a cargo, compositions for directing cargos to the lymphatic system, and vaccines. The methods of the invention can be used to increase an immune response, or to treat cancer or an infectious disease.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: May 9, 2023
    Assignee: Massachusetts Institute of Technology
    Inventors: Kelly Dare Moynihan, Rebecca Lynn Holden, Darrell J. Irvine, Bradley Lether Pentelute
  • Patent number: 11639372
    Abstract: The present invention is generally directed to chemically synthesized peptides that are charged with zinc ions (herein “zinc-charged peptides”). The chemically synthesized peptides are based on the amino acid sequence of alpha-lactalbumin. The present invention is further directed to a method of preparing these two zinc-charged peptides by charging the chemically synthesized peptides with zinc ions. It is observed that charging these peptides with zinc ions activate the peptide's ability to induce apoptosis in cancer cell lines, as well as increase ATP, reduce Tau protein and inhibit P38 in the brain. The zinc-charged peptides are thus capable of treating cancer and diseases involving tauopathy such as Alzheimer's Disease. The present invention is thus further directed to a method of treating cancer and diseases involving tauopathy such as Alzheimer's Disease using the zinc-charged peptides.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: May 2, 2023
    Inventor: Men Hwei Tsai
  • Patent number: 11638697
    Abstract: Disclosed herein are solid oral dosage formulations comprising sodium sulfate, magnesium sulfate, and potassium chloride for inducing purgation of the colon of a subject. Furthermore, the disclosed compositions and formulations are useful to cleanse the colon when administered in sufficient quantities. Methods for inducing purgation of the colon and for cleansing the colon are also disclosed.
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: May 2, 2023
    Assignee: Braintree Laboratories, Inc.
    Inventors: Mark vB Cleveland, Edmund V. Dennett, Jr., Russell W Pelham
  • Patent number: 11634470
    Abstract: The disclosure relates to integrin binding peptides, pharmaceutical compositions comprising the peptides and to uses thereof as therapeutic, diagnostic, imaging and targeting agents.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: April 25, 2023
    Assignees: Universiteit Twente
    Inventor: Jai Prakash
  • Patent number: 11633459
    Abstract: The present invention relates to novel peptides that are derivatives of glucose-dependent insulinotropic polypeptide (GIP) analogues having improved physical stability in solution and a protracted profile of action. More particular the invention relates to such peptides that are agonists at the GIP receptor and to their use in weight management or for treatment of diseases such as obesity, diabetes or non-alcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: April 25, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Wouter Frederik Johan Hogendorf, Henning Thoegersen, Nicholas Raymond Cox, Patrick J. Knerr, Richard Dimarchi, Brian Finan, Jesper F. Lau, Steffen Reedtz-Runge, Fa Liu
  • Patent number: 11634458
    Abstract: The present invention relates to a family of peptides which are able to interfere in the formation of complex Munc18-Syntaxin-1 and, hence, are useful in the prevention and/or treatment of neuronal exocytosis and/or muscle contractility disorders; and to prevent, reduce and/or eliminate skin aging and/or expression signs.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: April 25, 2023
    Assignee: LIPOTRUE, S.L.
    Inventors: Ariadna Grau-Campistany, Silvia Pastor, Patricia Carulla, Juan Carlos Escudero, Julia A. Boras, Isabel Devesa Giner, Gregorio Fernandez Ballester
  • Patent number: 11612661
    Abstract: Provided herein are alpha-conotoxin peptide analogs, including alpha-conotoxin peptide analogs that are covalently attached to polyethylene glycol (PEG), and pharmaceutical compositions of such alpha-conotoxin peptide analogs. Also provided herein are methods of treating or preventing a condition conducive to treatment or prevention by inhibition of an ?9-containing nicotinic acetylcholine receptor (nAChR) (e.g., the ?9?10 subtype of the nAChR) in a subject.
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: March 28, 2023
    Assignee: Kineta Chronic Pain, LLC
    Inventors: Jose Mercado, Eric J. Tarcha, Jeffrey J. Posakony, Shawn Iadonato
  • Patent number: 11612640
    Abstract: Provided are a GLP-1(7-37) polypeptide analogue, a fatty acid-modified derivative of the analogue, and a medicament comprising the derivative. Further, also provided are a preparation method of the derivative, and use of the same in the preparation of a medicament.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: March 28, 2023
    Assignee: SCIWIND BIOSCIENCES CO., LTD.
    Inventors: Zheng Xu, Feng Li, Rui Song, Wanjun Guo, Hai Pan, Jing Feng
  • Patent number: 11612628
    Abstract: The present invention relates to new compositions suitable for use in the treatment of articular disorders (or conditions), processes for preparing said compositions and use of said compositions in therapeutic treatments of articular disorders.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: March 28, 2023
    Assignee: Aboca S.p.A. Società Agricola
    Inventors: Valentino Mercati, Carla Ghelardini, Lorenzo Di Cesare Mannelli
  • Patent number: 11613567
    Abstract: Described herein are Notch-modulating peptides (including monomers and multimers) capable of increasing or decreasing an immune response in a subject, compositions comprising the peptides, and methods of use thereof.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: March 28, 2023
    Assignee: Ohio State Innovation Foundation
    Inventors: Thomas J. Magliery, Mikhail M. Dikov, David Carbone, Nicholas Long, Brandon Sullivan, Elena Tchekneva
  • Patent number: 11608371
    Abstract: The present invention relates to effective pain therapies in companion animals. In particular, an isolated companion animal p75NTR protein or a fusion protein containing the same or portions thereof are contemplated. Nucleic acids encoding the proteins are also encompassed in the invention as well as methods of using the same.
    Type: Grant
    Filed: October 21, 2021
    Date of Patent: March 21, 2023
    Assignee: PETMEDIX LTD
    Inventors: Meng Amy Li, Marco Bardelli
  • Patent number: 11602512
    Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: March 14, 2023
    Assignee: Flamel Ireland Limited
    Inventors: Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François Dubuisson
  • Patent number: 11602513
    Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
    Type: Grant
    Filed: October 8, 2021
    Date of Patent: March 14, 2023
    Assignee: Flamel Ireland Limited
    Inventors: Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François Dubuisson
  • Patent number: 11596648
    Abstract: This invention relates generally to an emollient topical composition of matter that contains molecular iodine with a reduced effective vapor pressure. In specific embodiments, the composition reduces the loss of molecular iodine to the atmosphere under storage conditions after application to mammalian tissue.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: March 7, 2023
    Assignee: I2PURE CORP.
    Inventors: Jack Kessler, David C. Litzinger, Christopher Rhodes, Andrew M. Cerro
  • Patent number: 11576950
    Abstract: The present invention relates to methods of using new doses of dulaglutide and compositions containing such higher doses of dulaglutide.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: February 14, 2023
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Cox, Zvonko Milicevic, Lai San Tham, David Bradley Woodward